无偏高维流式细胞术鉴定出 A 型乳腺癌和三阴性乳腺癌中的 NK 和 DC 免疫细胞特征

IF 7.2 2区医学

Oncoimmunology Pub Date : 2023-12-22 DOI:10.1080/2162402x.2023.2296713

L. Heger, Gordon F Heidkamp, L. Amon, F. Nimmerjahn, Tobias Bäuerle, Andreas Maier, R. Erber, A. Hartmann, C. Hack, M. Ruebner, H. Huebner, Peter Fasching, Matthias W. Beckmann, Diana Dudziak

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Unbiased high-dimensional flow cytometry identified NK and DC immune cell signature in Luminal A-type and triple negative breast cancer

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.